ALPS Medical Breakthroughs ETF (SBIO) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores SBIO 1.8 out of 10 — highest on Return (4.6), lowest on Quality (0.3). Its ten largest holdings are 31% of the fund.
What stands out in SBIO's data
Tracks U.S. biotech clinical-stage firms focused on high-risk innovation.
Earnings margins trail most peers — the fund's small-cap bets carry real business risk.
EBITDA margin of 2.0% sits behind most peers and below its own historical median of 6.2%. Charges 0.50% annually.
Provides a focused biotech innovation allocation for a portfolio already holding broader health-care exposure.
Why did SBIO move this week? It fell 2.0% in the week to October 9, 2026 — Travere Therapeutics and Arrivent Biopharma drove it
SBIO fell 2.0% in the week to October 9, 2026. The holdings that moved it most were Travere Therapeutics (−8.4%), Arrivent Biopharma (−40.8%) and Dianthus Therapeutics (−6.6%); Veradermics (+12.1%) pushed the other way.
How is SBIO rated? ETF Copilot scores ALPS Medical Breakthroughs ETF (SBIO) 1.8 out of 10
As of October 9, 2026, ETF Copilot scores ALPS Medical Breakthroughs ETF (SBIO) 1.8 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 1.8 / 10
- Risk: 0.7 / 10
- Quality: 0.3 / 10
- Return: 4.6 / 10
What's inside SBIO?
What's inside SBIO: Size (Large 0%, Mid 11%, Small 89%); Geography (International 11%, US 89%).
What are SBIO's top holdings? The ten largest are 31% of the fund
CG Oncology, Veradermics, Oruka Therapeutics, Travere Therapeutics, Dianthus Therapeutics, Definium Therapeutics, Edgewise Therapeutics, Relay Therapeutics, Xenon Pharmaceuticals and Ideaya Biosciences are SBIO's largest holdings, in that order.
Less concentrated than 78% of Health & Biotech ETFs.
Half of SBIO's weight sits in its 21 largest positions, and once those weights are taken into account it behaves like 55 equally weighted holdings.
What is SBIO's expense ratio? 0.50% a year
As of October 9, 2026, SBIO charges 0.50% a year and holds $187M in assets across 104 positions.
| Measure | SBIO |
|---|---|
| Expense ratio | 0.50% |
| Assets under management | $187M |
| Holdings | 104 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “ALPS Medical Breakthroughs ETF (SBIO) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/sbio
ETF Copilot Pro unlocks SBIO's price and what each holding weighs.
Try Pro free →